Retatrutide, a novel dual-acting glucose-regulated incretin analog, represents a significant progression in peptide treatments for the management of type 2 sugar disorders and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor stimulant, offering a